Compare PUSA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUSA | ICCC |
|---|---|---|
| Founded | N/A | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.4M | 93.1M |
| IPO Year | 2024 | 1995 |
| Metric | PUSA | ICCC |
|---|---|---|
| Price | $3.67 | $9.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 528.1K | 25.6K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | $2,964,377.00 | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.17 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $2.60 | $4.52 |
| 52 Week High | $4.45 | $12.10 |
| Indicator | PUSA | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 41.20 |
| Support Level | $3.64 | $9.27 |
| Resistance Level | $3.87 | $10.75 |
| Average True Range (ATR) | 0.24 | 0.27 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 49.44 | 17.03 |
Aureus Greenway Holdings Inc own and operate two public golf country clubs in Florida. The golf country clubs include two golf-courses with over 13,000 yards of combined fairways, clubhouses boasting food and beverage options, aquatic golf ranges, and pro shops to assist any level of golfer and also host local golf leagues, golf-tournaments, and private events. Its golf country clubs is organized into four principal business segments: (i) golf recreation, retail golf products, and equipment and facilities rental, (ii) membership dues, (iii) food and beverage services. and (iv) ancillary services and amenities. All assets of the Company are located in Florida and all revenue is generated from Florida.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.